|Bid||152.00 x 200|
|Ask||154.99 x 100|
|Day's Range||153.79 - 154.99|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||14.68|
|Dividend & Yield||4.60 (3.01%)|
|1y Target Est||N/A|
Amgen is a great dividend stock. Here's why Gilead Sciences is even better.
In 1Q17, Neupogen generated revenues of ~$148 million, a significant drop from the drug’s 1Q16 revenues of ~$213 million.
According to a March 2016 report by QuintilesIMSHealth, the biologics market is estimated to reach $390 billion by 2020.